James R. Neal
James R. Neal's purchase track record
James R. Neal has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/31/2026 | PCSA | $2K | -24.0% | -30.3% | +17.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Akari Therapeutics Files New Patent Application. Akari Therapeutics has submitted a new patent application to expand its intellectual property portfolio. This move is relevant as it aims to strengthen the company's long-term position in its therapeutic areas. The stock currently trades well below its 52-week high, reflecting the significant volatility seen in the sector.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Palisade Bio Gets FDA and Health Canada Clearances for PALI-2108. Palisade Bio received FDA clearance for an IND to test PALI-2108 in Crohn’s disease, with first enrollment expected in Q1 next year. The company also secured Health Canada clearance for its Phase 2b ulcerative colitis trial. These regulatory approvals expand the drug's development across inflammatory bowel disease, while the stock remains near its 52-week low.
Transaction History
| PCSA | ▲ Buy | Option Exercise | 203 | — | 6/26/2026 | View on chart |
| PCSA | ▲ Buy | Open Market | 789 | $2K | 3/31/2026 | View on chart |
| AKTX | ▲ Buy | Grant | 4,464 | $5K | 3/6/2025 | View on chart |
| AKTX | ▲ Buy | Grant | 8,000,000 | $5K | 1/9/2025 | View on chart |
| AKTX | ▲ Buy | Grant | 2,000,000 | $1K | 12/23/2024 | View on chart |
| PALI | ▲ Buy | Option Exercise | 5,100 | $0 | 2/9/2024 | View on chart |
| PALI | ▲ Buy | Option Exercise | 5,820 | $0 | 2/9/2024 | View on chart |
| PCSA | ▲ Buy | Option Exercise | 14,407 | — | 6/27/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Processa Files Prospectus for 306.5M Share Offering
Processa Pharmaceuticals filed a prospectus for an offering of 306.574 million common shares on behalf of selling shareholders. This large-scale secondary offering adds significant supply to the market, which may pressure the stock price. The company is currently trading near the lower end of its 52-week range, with technical indicators showing weakness.
Processa Files Prospectus for 306.5M Share Offering. Processa Pharmaceuticals filed a prospectus for an offering of 306.574 million common shares on behalf of selling shareholders. This large-scale secondary offering adds significant supply to the market, which may pressure the stock price. The company is currently trading near the lower end of its 52-week range, with technical indicators showing weakness.